|
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs Clinical research trials and A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs. A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs clinical trial. Participants oftentimes recieve the finest healthcare available for their A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs  A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs
For Condition: HIV Infections
Status: No longer recruiting
Sponsor(s): Bristol-Myers Squibb ,
Synopsis: The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF. This study also examines how long these drug combinations are effective in lowering viral load (level of HIV in the blood).
Details:
Eligibility:
Study Type: Interventional, Treatment, Safety Study
Minimum Age/Maximum Age: 12 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Patients must have: Within 15 business days prior to randomization: - CD4 cell count greater than or equal to 100 cells/mm3. - HIV RNA greater than or equal to 2,000 copies/ml by Roche Amplicor Assay. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - Bilateral peripheral neuropathy. - Intractable diarrhea. - Proven or suspected acute hepatitis within 30 days prior to study entry. Concurrent Medication: Excluded: Therapy for any co-existing disease that may interfere with patient ability to participate in this study. Concurrent Treatment: Excluded: Therapy for any co-existing disease that may interfere with patient ability to participate in this study. Patients with the following prior conditions are excluded: History of acute or chronic pancreatitis. Prior Medication: Excluded: - Therapy for any previous disease that may interfere with patient ability to participate in this study. - Excluded within 14 days prior to randomization: Greater than 4 weeks of nucleoside therapy or greater than 1 week of protease inhibitor therapy. - Excluded within 3 months of the start of this study or expected need at time of enrollment: - Agents with significant systemic myelosuppressive, neurotoxic, pancreatoxic, hepatotoxic, or cytotoxic potential. - Inability to tolerate oral medication. Prior Treatment: Excluded: Therapy for any previous disease that may interfere with patient ability to participate in this study. Risk Behavior: Excluded: Active alcohol or substance abuse that, in the opinion of the investigator, is sufficient to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis.
Total Enrollment:
Location and Contact Information:
St Luke Roosevelt Hosp
New York City, New York, 10011
United States
Yale New Haven Hosp / Nathan Smith Clinic
New Haven, Connecticut, 06504
United States
St Mary's Hosp (Univ of Rochester/Infectious Diseases)
Rochester, New York, 14642
United States
Nalle Clinic / Clinical Research Dept
Charlotte, North Carolina, 28207
United States
West Los Angeles VAMC
Los Angeles, California, 90073
United States
Med Alternatives
Ft. Lauderdale, Florida, 33308
United States
SUNY at Stony Brook / Div of Infectious Disease
Stony Brook, New York, 117948153
United States
Saint Josephs Hosp
Tampa, Florida, 33602
United States
Hillsborough County Health Dept
Tampa, Florida, 33602
United States
Specialty Med Care Ctrs of South Florida Inc
Miami, Florida, 33142
United States
Hill Top Research Inc
Fresno, California, 93710
United States
UCLA Med Ctr / CARE BH-412 CHS
Los Angeles, California, 90024
United States
Infectious Disease Assoc of Central Jersey
Somerville, New Jersey, 08876
United States
AIDS Healthcare Foundation
Los Angeles, California, 900276069
United States
Urgent Care Ctr
Ft. Lauderdale, Florida, 33316
United States
Univ of Texas / Med Branch at Galveston
Galveston, Texas, 775550835
United States
Dartmouth-Hitchcock Med Ctr
Lebanon, New Hampshire, 03756
United States
Joseph C Gathe
Houston, Texas, 77004
United States
Body Positive
Phoenix, Arizona, 85016
United States
Univ of Kansas School of Medicine / Office of Rsch
Wichita, Kansas, 67214
United States
Associates in Med and Mental Health
Tulsa, Oklahoma, 74114
United States
Ky Clinic Annex #4 / Room 205E / Speed Sort #0284
Lexington, Kentucky, 405360226
United States
Sherman Oaks Hosp Research Institute
Sherman Oaks, California, 91403
United States
Med Univ of South Carolina / Div of Infect Disease
Charleston, South Carolina, 29425
United States
Northwestern Univ / Div of Infect Diseases
Chicago, Illinois, 60611
United States
Sorra Research Ctr / Med Forum
Birmingham, Alabama, 35203
United States
Stephen P Hauptman
Philadelphia, Pennsylvania, 19107
United States
UCT International
Farmingdale, New York, 11735
United States
Harbor UCLA Med Ctr / Research and Educational Institute
Torrance, California, 90502
United States
Rush Presbyterian / ST Lukes Med Ctr
Chicago, Illinois, 60612
United States
NJCRI
Newark, New Jersey, 07103
United States
GW Med Ctr / Clinical Trials Unit
Washington D.C., District of Columbia, 20037
United States
Additional Information:
Study ID Numbers: 039E; AI454-148
Study Start Date:
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002411
Other Hiv Infections Studies:
1. Underlying abnormalities in fat and muscle leading to Lipodystrophy Syndrome
2. Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection
3. A Trial of Alternating 2',3'-Dideoxycytidine and Zidovudine in the Treatment of Patients With Advanced HIV Disease
4. A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.
5. Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients
Related Studies:
Other HIV Infections Clinical Trials
Other Connecticut Clinical Trials
Other New Haven Clinical Trials
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated with Anti-HIV Drugs
|
|
|
|
|
|
|
|
